Our platform therapy, YourVaccx™ utilizes a proprietary procedure that combines the ANTIGENerator™ for controlled cell lysis with a triple-component immunotherapeutic drug.
We are developing this radically new operating system for immunotherapy initially for the treatment of metastatic prostate cancer with a pipeline of additional development programs for other metastatic solid tumor cancers.
YourVaccx™: Cancer Therapy Powered By You
The YourVaccx therapy empowers the patient’s immune system to create a personal in-situ autologous vaccine that attacks cancer throughout the entire body. The following illustration depicts an overview of the steps involved in the therapy:
A segment of a tumor is lysed, liberating tumor antigens and other molecules that serve to activate the immune system.
A triple-component immunotherapeutic drug is injected into the disrupted tumor.
This combination approach empowers the immune system to create an in-situ autologous vaccine that drives an abscopal effect that attacks the metastatic cancer throughout the body.
The animation below provides a more detailed description of the therapy and how it works to fight cancer.
Disclaimers: The content on this website is intended for US healthcare professionals only. YourVaccx™ and any other trade names mentioned in this website are not approved by the US Food and Drug Administration.
The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the US Food and Drug Administration.